Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+Status: Updated Results from the Phase 3 IKEMA Study

被引：0

作者：

Facon, Thierry ^{[1
]}

Moreau, Philippe ^{[2
]}

Spicka, Ivan ^{[3
]}

Suzuki, Kenshi ^{[4
]}

Yong, Kwee ^{[5
]}

Mikhael, Joseph ^{[6
]}

Fukao, Taro ^{[7
]}

Bisht, Kamlesh ^{[7
]}

Armstrong, Nicole ^{[8
]}

Mace, Sandrine ^{[9
]}

Risse, Marie-Laure ^{[10
]}

Martin, Thomas ^{[11
]}

机构：

[1] Lille Univ Hosp, Dept Hematol, Lille, France

[2] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[3] Charles Univ & Gen Hosp, Fac Med 1, Dept Hematol, Prague, Czech Republic

[4] Japanese Red Cross Med Ctr, Myeloma Amyloidosis Ctr, Tokyo, Japan

[5] Univ Coll Hosp, Dept Haematol, London, England

[6] City Hope Canc Ctr, Translat Genom Res Inst, Phoenix, AZ USA

[7] Sanofi, Global Oncol, Cambridge, MA USA

[8] Sanofi, Global Med Affairs, Cambridge, MA USA

[9] Sanofi, Res & Dev, Chilly Mazarin, France

[10] Sanofi, Res & Dev, Vitry Sur Seine, France

[11] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

1q21; IKEMA; isatuximab; carfilzomib; dexamethasone; multiple myeloma; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-248

引用

页码：S484 / S485

页数：2

共 50 条

[1] Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) In Relapsed Multiple Myeloma Patients With 1q21+Status: Updated Results From The Phase 3 IKEMA Study
Thierry, Facon
Philippe, Moreau
Ivan, Spicka
Kenshi, Suzuki
Kwee, Yong
Joseph, Mikhael
Taro, Fukao
Kamlesh, Bisht
Nicole, Armstrong
Sandrine, Mace
Marie-Laure, Risse
Thomas, Martin
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S26 - S26
[2] Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+status: Updated results from the phase 3 IKEMA study.
Facon, Thierry
Moreau, Philippe
Spicka, Ivan
Suzuki, Kenshi
Yong, Kwee
Mikhael, Joseph
Fukao, Taro
Bisht, Kamlesh
Armstrong, Nicole
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Isatuximab in combination with carfilzomib and dexamethasone in 1q21+patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study
Facon, Thierry
Moreau, Philippe
Spicka, Ivan
Suzuki, Kenshi
Yong, Kwee
Mikhael, Joseph
Fukao, Taro
Bisht, Kamlesh
Armstrong, Nicole M.
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas
HEMATOLOGICAL ONCOLOGY, 2024, 42 (02)
[4] Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Martin, Thomas
Dimopoulos, Meletios-Athanasios
Mikhael, Joseph
Yong, Kwee
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Baker, Ross
Kim, Kihyun
Martinez, Gracia
Min, Chang-Ki
Pour, Ludek
Leleu, Xavier
Oriol, Albert
Koh, Youngil
Suzuki, Kenshi
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Moreau, Philippe
BLOOD CANCER JOURNAL, 2023, 13 (01)
[5] Updated Progression-free Survival (PFS) and Depth of Response in IKEMA, A Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma (MM)
Mikhael, Joseph
Moreau, Philippe
Dimopoulos, Meletios-Athanasios
Yong, Kwee
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S37 - S38
[6] Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Thomas Martin
Meletios-Athanasios Dimopoulos
Joseph Mikhael
Kwee Yong
Marcelo Capra
Thierry Facon
Roman Hajek
Ivan Špička
Ross Baker
Kihyun Kim
Gracia Martinez
Chang-Ki Min
Ludek Pour
Xavier Leleu
Albert Oriol
Youngil Koh
Kenshi Suzuki
France Casca
Sandrine Macé
Marie-Laure Risse
Philippe Moreau
Blood Cancer Journal, 13
[7] Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Yong, Kwee
Moreau, Philippe
Dimopoulos, Meletios A.
Mikhael, Joseph
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S194 - S195
[8] Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma
Martin, Thomas
Dimopoulos, Meletios-Athanasios
Mikhael, Joseph
Yong, Kwee
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S403 - S404
[9] VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Moreau, P.
Dimopoulos, M. A. C.
Mikhael, J.
Yong, K.
Capra, M.
Facon, T.
Hajek, R.
Spicka, I.
Casca, F.
Mace, S.
Singh, E.
Risse, M-L.
Martin, T.
ANNALS OF ONCOLOGY, 2022, 33 (06) : 664 - 665
[10] Primary outcomes by 1q21+status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
Martin, Tom
Richardson, Paul G.
Facon, Thierry
Moreau, Philippe
Perrot, Aurore
Spicka, Ivan
Bisht, Kamlesh
Inchauspe, Marlene
Casca, France
Mace, Sandrine
van de Velde, Helgi
Suzuki, Kenshi
HAEMATOLOGICA, 2022, 107 (10) : 2485 - 2491

← 1 2 3 4 5 →